let's be realistic..., page-6

I think its a likely scenario. Why wouldn't DRR and ACL come to an agreement to buy the fonda rights? It's not going to be another generic company when ACL has a sales agreement with DRR worldwide. And it's DRR's bread and butter business, not ACL's. It would be much better for ACL to convert future payments into an upfront divestment, allowing them to proceed with the stream of Hyact trials.

It would also explain the puzzling demerger. Apart from the vague possibility of forcing the market to value each component appropriately (which strikes me as a strange lack of confidence in market forces), it's hard to come up with a reason apart from packaging the fonda business for sale.

Treasure's previous post about the Board's visit to India may be on the button! (where DOES he/she get their info??)

Watch this space.